-
1 Comment
genedrive plc is currently in a long term downtrend where the price is trading 34.9% below its 200 day moving average.
From a valuation standpoint, the stock is 90.8% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 41.1.
genedrive plc's total revenue sank by 0.0% to $314K since the same quarter in the previous year.
Its net income has dropped by 0.0% to $-2M since the same quarter in the previous year.
Finally, its free cash flow fell by 146.5% to $-2M since the same quarter in the previous year.
Based on the above factors, genedrive plc gets an overall score of 1/5.
| Exchange | LSE |
|---|---|
| CurrencyCode | GBP |
| ISIN | GB00B1VKB244 |
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Beta | 1.58 |
|---|---|
| Market Cap | 8M |
| PE Ratio | None |
| Target Price | 85 |
| Dividend Yield | None |
genedrive plc engages in the design, development, and manufacture of molecular diagnostics testing equipment for use in genotyping, pathogen detection, infectious disease detection, and other clinical indications. The company provides c system, rapid nucleic acid thermocycler and fluorescence signal detection system for target discrimination used for qualitative in vitro molecular diagnostic tests; and Genedrive CYP2C19 ID Kit, a certified test for identification of individuals unlikely to respond to the commonly prescribed antiplatelet drug Clopidogrel. It offers Genedrive MT-RNR1-ID Kit, a rapid genetic test in an emergency neonatal care setting; and tests for the detection of Antibiotic Induced Hearing Loss in neonates, confirmation of HCV infection prior to drug administration, pathogen detection of biological military threats and a point-of-care for COVID-19 detection system for use in areas, such as healthcare, workplace screening, travel requirements, and confirmation of antigen tests. It serves medical, biotechnology, and pharmaceutical industries in the United Kingdom, Europe, the United States, and internationally. The company was formerly known as Epistem Holdings Plc and changed its name to genedrive plc in July 2016. The company was founded in 2000 and is headquartered in Manchester, the United Kingdom.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for GDR.LSE using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
